IV vs IM injections for peptides: what the evidence says

What's this video probably claiming?

Based on the caption and the peptide-adjacent creator context, this video is almost certainly walking viewers through the differences between intravenous (IV) and intramuscular (IM) injection routes, likely in the context of peptide administration. Creators in this space typically argue that IV delivery offers faster onset and higher bioavailability, while IM is more accessible and safer for self-administration. There may be claims about which route is "better" for specific peptides like BPC-157, TB-500, or GHK-Cu, and possibly some hand-waving about absorption kinetics. The framing, especially from a creator with a medical-sounding handle, often implies clinical authority that the evidence base for most peptide therapies does not yet support. Expect confident delivery of pharmacokinetic generalizations that are true for some drugs but have not been validated specifically for most research-grade peptides used in wellness contexts.

What does the science actually show?

Injection route genuinely matters for bioavailability, but the details are drug-specific and context-dependent. IV administration delivers 100% bioavailability by definition, bypassing first-pass metabolism entirely. IM injections show bioavailability ranging from 50% to over 90% depending on the molecule's molecular weight, lipophilicity, and local tissue perfusion (Kaplan et al., 2016, Journal of Pharmaceutical Sciences). For peptides specifically, IM absorption is slowed by protease activity at the injection site. A 2019 review in Drug Delivery noted that short-chain peptides under 1,000 Da degrade significantly in muscle tissue before systemic absorption. BPC-157 and TB-500 have been studied almost exclusively in rodent models via intraperitoneal injection, not IM or IV in humans, meaning direct translation of route-specific claims to human peptide therapy is speculative. Subcutaneous injection, absent from most of these social media comparisons, actually shows comparable bioavailability to IM for many peptides and carries a lower adverse event profile.

Where does the social media noise diverge from clinical reality?

The core problem with IV-versus-IM content in peptide communities is that it borrows legitimacy from well-established pharmacology and applies it to compounds with almost no human pharmacokinetic data. Saying IV is faster than IM is true for lidocaine. For BPC-157 in humans? We do not have the data. The creator may also be implying that viewers can make informed self-administration choices based on this comparison, which is a serious red flag. IV self-administration outside a clinical setting carries real risks: air embolism, catheter-related bloodstream infections (CRBSI rates in home IV therapy range from 0.4 to 1.0 per 1,000 catheter days, per Maki et al., 2006, JAMA), vein damage, and sepsis. IM is safer comparatively, but improper technique still causes abscess, nerve injury, and hematoma. Neither route should be presented as a casual DIY choice, and framing them as interchangeable consumer options misrepresents the actual risk profile involved.

What should you actually know?

If you are considering peptide therapy, the injection route question should be answered by a licensed prescriber who has reviewed your specific compound, your vascular access, and your medical history, not a TikTok video. For most peptide therapies currently offered through regulated telehealth channels, subcutaneous injection is the standard of care precisely because it is safer and easier to administer correctly. IV peptide infusions in legitimate clinical settings are supervised, use sterile compounded preparations, and involve monitoring for adverse reactions. Any content that positions IV versus IM as a consumer-level decision is skipping several steps. Compounded peptides are not FDA-approved drugs, and bioavailability claims made about brand-name injectable drugs do not automatically transfer. Ask your provider specifically which route is indicated for your prescribed compound, at what concentration, and why.